Mengya Y. Zang
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients.
Journal: The Journal of infectious diseases
Published: October 16, 2025
Outcomes of RALOX-HAIC-based Combination Therapy for Unresectable Hepatocellular Carcinoma with Radiomics-Powered Prediction.
Journal: Academic radiology
Published: September 21, 2025
Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP.
Journal: International journal of surgery (London, England)
Published: March 03, 2025
Camrelizumab Combined with Lenvatinib and RALOX-Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma (Cal Era): A Prospective, Single-Arm, Phase II Trial.
Journal: Liver cancer
Published: February 23, 2025
Low-Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: December 22, 2024
Cadonilimab (PD-1/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study.
Journal: Heliyon
Published: June 20, 2024
Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer
Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Published: January 19, 2024
Unveiling the Research Landscape and Emerging Trends in Cell Cycle for Cancer Immunotherapy: A Bibliometric Analysis (1990-2022).
Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: December 01, 2023
Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
Journal: International immunopharmacology
Published: July 08, 2023
A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma.
Journal: Signal transduction and targeted therapy
Published: July 04, 2023
Last Updated: 09/26/2026